Nalaganje...
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those wi...
Shranjeno v:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Hindawi Publishing Corporation
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003830/ https://ncbi.nlm.nih.gov/pubmed/25093123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/931858 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|